RU2016116533A - Новые соединения и композиции для ингибирования nampt - Google Patents
Новые соединения и композиции для ингибирования nampt Download PDFInfo
- Publication number
- RU2016116533A RU2016116533A RU2016116533A RU2016116533A RU2016116533A RU 2016116533 A RU2016116533 A RU 2016116533A RU 2016116533 A RU2016116533 A RU 2016116533A RU 2016116533 A RU2016116533 A RU 2016116533A RU 2016116533 A RU2016116533 A RU 2016116533A
- Authority
- RU
- Russia
- Prior art keywords
- pyridin
- urea
- phenyl
- ylmethyl
- sulfonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
- C07C317/42—Y being a hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
Claims (65)
1. Соединение, выбранное из группы, состоящей из:
N-[2-(пиридин-3-ил)этил]-4-{[3-(трифторметокси)бензол]сульфонил}бензамида;
3-[4-(бензолсульфонил)фенил]-1-{[6-(1H-пиразол-1-ил)пиридин-3-ил]метил}мочевина;
4-(бензолсульфонил)-N-{имидазо[1,2-a]пиридин-7-илметил}бензамида;
4-(бензолсульфонил)-N-(пиридин-3-илметил)бензамида;
3-[4-(бензолсульфонил)фенил]-1-{[6-(1H-имидазол-1-ил)пиридин-3-ил]метил}мочевины;
3-{[({4-[(4-хлорбензол)сульфинил]фенил}карбамоил)амино]метил}пиридин-1-ий-1-олата;
1-[4-(бензолсульфонил)фенил]-3-(1H-пиразол-3-илметил)мочевины;
N-{имидазо[1,2-a]пиридин-6-илметил}-4-{[3-(трифторметокси)бензол]сульфонил}бензамида;
1-{[4-(бензолсульфонил)фенил]метил}-3-(хинолин-6-ил)мочевины;
1-[(3-аминофенил)метил]-3-[4-(бензолсульфонил)фенил]мочевины;
3-{4-[(4-хлорбензол)сульфинил]фенил}-1-(пиридин-3-илметил)мочевины;
4-[(2-хлорбензол)сульфонил]-N-{имидазо[1,2-a]пиридин-6-илметил}бензамида;
4-[(3-хлорбензол)сульфонил]-N-{имидазо[1,2-a]пиридин-6-илметил}бензамида;
1-[4-(бензолсульфонил)фенил]-3-{имидазо[1,2-a]пиридин-6-илметил}мочевины;
3-(4-{[3-фтор-4-(1H-пиразол-1-ил)бензол]сульфонил}фенил)-1-(пиридин-3-илметил)мочевины;
3-[4-(бензолсульфонил)фенил]-1-(хинолин-6-ил)мочевины;
1-{4-[(4-фторбензол)сульфонил]фенил}-3-{имидазо[1,2-a]пиридин-6-илметил}мочевины;
N-{имидазо[1,2-a]пиридин-6-илметил}-4-{[3-(трифторметил)бензол]сульфонил}бензамида;
4-[(3,5-дифторбензол)сульфонил]-N-{имидазо[1,2-a]пиридин-6-илметил}бензамида;
N-{имидазо[1,2-a]пиридин-6-илметил}-4-[(3-метоксибензол)сульфонил]бензамида;
N-(1,3-бензотиазол-6-илметил)-4-[(3-хлорбензол)сульфонил]бензамида;
1-[4-(бензолсульфонил)фенил]-3-{тиено[2,3-c]пиридин-2-илметил}мочевины;
1-(4-бензоилфенил)-3-(пиридин-3-илметил)мочевины;
3-[4-(бензолсульфонил)фенил]-1-(пиридин-3-ил)мочевины;
4-(бензолсульфонил)-N-(пиридин-3-ил)бензамида;
4-(бензолсульфонил)-N-(пиридин-4-ил)бензамида;
3-{имидазо[1,2-a]пиридин-6-илметил}-1-{4-[4-(морфолин-4-ил)пиперидин-1-сульфонил]фенил}мочевины;
N-{имидазо[1,2-a]пиридин-6-илметил}-4-{8-окса-3-азабицикло[3,2,1]октан-3-сульфонил}бензамида;
1-[(3,4-дифторфенил)метил]-3-[4-(пиперидин-1-сульфонил)фенил]мочевины;
4-(пиперидин-1-сульфонил)фенил-N-(пиридин-3-илметил)карбамата;
3-[4-(пиперидин-1-сульфонил)фенил]-1-[1-(пиридин-3-ил)этил]мочевины;
3-[4-(пиперидин-1-сульфонил)фенил]-1-[2-(пиридин-3-ил)этил]мочевины;
3-[2-фтор-4-(пиперидин-1-сульфонил)фенил]-1-(пиридин-3-илметил)мочевины;
пиридин-3-илметил-N-[4-(пиперидин-1-сульфонил)фенил]карбамата;
3-бензил-1-[4-(пиперидин-1-сульфонил)фенил]мочевины;
N-[4-(пиридин-3-ил)-1,3-тиазол-2-ил]-4-(1,2,3,4-тетрагидроизохинолин-2-сульфонил)бензамида;
метил-4-{[(пиридин-3-илметил)карбамоил]амино}бензоат;
rel-3-{4-[(2R,6S)-2,6-диметилморфолин-4-сульфонил]фенил}-1-(пиридин-3-илметил)мочевины;
3-[4-(пиперидин-1-сульфонил)фенил]-1-(пиразин-2-илметил)мочевины;
3-{имидазо[1,2-a]пиридин-6-илметил}-1-(4-{3-окса-8-азабицикло[3.2.1]октан-8-сульфонил}фенил)мочевины;
3-[(2-фторфенил)метил]-1-[4-(пиперидин-1-сульфонил)фенил]мочевины;
1-[(6-изоцианопиридин-3-ил)метил]-3-[4-(пиперидин-1-сульфонил)фенил]мочевины;
1-[(4-фторфенил)метил]-3-[4-(пиперидин-1-сульфонил)фенил]мочевины;
N-[2-(пиридин-3-ил)этил]-4-{[3-(трифторметокси)фенил]сульфамоил}бензамида;
3-{[4-(пиперидин-1-сульфонил)фенил]метил}-1-(пиридин-3-ил)мочевины;
1-{4-[(пиперидин-1-ил)карбонил]фенил}-3-(пиридин-3-илметил)мочевины;
3-[(3-фторфенил)метил]-1-[4-(пиперидин-1-сульфонил)фенил]мочевины;
4-[(3-хлорфенил)сульфамоил]-N-{имидазо[1,2-a]пиридин-6-илметил}бензамида;
3-{имидазо[1,2-a]пиридин-6-илметил}-1-(4-{8-окса-3-азабицикло[3.2.1]октан-3-сульфонил}фенил)мочевины;
3-{4-[(2R,6S)-2,6-диметилморфолин-4-сульфонил]фенил}-1-(пиридин-3-илметил)мочевины;
N-{имидазо[1,2-a]пиридин-6-илметил}-4-{[3-(трифторметокси)фенил]сульфамоил}бензамида; и
4-[(5-хлор-2-метоксифенил)сульфамоил]-N-{имидазо[1,2-a]пиридин-6-илметил}бензамида,
или его фармацевтически приемлемой соли.
2. Фармацевтическая композиция, обладающая способностью ингибировать никотинамидфосфорибозилтрансферазу (“NAMPT”), включающая терапевтически эффективное количество соединения по п.1 и фармацевтически приемлемый носитель.
3. Фармацевтическая композиция по п.2, дополнительно включающая химиотерапевтическое средство.
4. Фармацевтическая композиция по п.3, где указанное химиотерапевтическое средство представляет собой ДНК-повреждающее средство.
5. Фармацевтическая композиция по п.2, дополнительно включающая спасающее клетки средство.
6. Фармацевтическая композиция по п.5, где указанное спасающее клетки средство выбрано из группы, включающей никотинамид, никотинамидмононуклеотид (NМN) и никотиновую кислоту.
7. Фармацевтическая композиция по п.3, где указанное химиотерапевтическое средство выбрано из группы, включающей следующие: цитотоксическое средство, цисплатин, доксорубицин, таксотере, таксол, этопозид, иринотекан, камптостар, топотекан, паклитаксел, доцетаксел, эпотилоны, тамоксифен, 5-фторурацил, метокстрексат, темозоломид, циклофосфамид, SCH 66336, типифарниб (Zarnestra®), R115777, L778,123, BMS 214662, Iressa®, Tarceva®, C225, GLEEVEC®, интрон®, Peg-Интрон®, соединения ароматазы, ara-C, адриамицин, цитоксан, гемцитабин, Урацил иприт, Хлорметин, Ифосфамид, Мелфалан, Хлорамбуцил, Пипоброман, Триэтиленмеламин, Триэтилентиофосфорамин, Бусульфан, Кармустин, Ломустин, Стрептозоцин, Дакарбазин, Флоксуридин, Цитарабин, 6-Меркаптопурин, 6-Тиогуанин, Флударабин фосфат, лейковирин, оксалиплатин (ELOXATIN®), Пентостатин, Винбластин, Винкристин, Виндезин, Блеомицин, Дактиномицин, Даунорубицин, Эпирубицин, Идарубицин, МитрамицинTM, Дезоксикоформицин, Митомицин-C, L-Аспарагиназа, Тенипозид 17α-Этинилэстрадиол, Диэтилстилбестрол, Тестостерон, Преднизон, Флуоксиместерон, Дромостанолон пропионат, Тестолактон, Мегестрол ацетат, Метилпреднизолон, Метилтестостерон, Преднизолон, Триамцинолон, Хлортрианисен, Гидроксипрогестерон, Аминоглутетимид, Эстрамустин, Медроксипрогестеронацетат, Лейпролид, Флутамид, Торемифен, госерелин, Карбоплатин, Гидроксимочевина, Амсакрин, Прокарбазин, Митотан, Митоксантрон, Левамизол, Навелбен, Анастразол, Летразол, Капецитабин, Релоксафин, Дролоксафин, Гексаметилмеламин, Авастин, герцептин, Бексар, Велкаде, Зевалин, Трисенокс, Кселода, Винорелбин, Порфимер, Эрбутукс, Липосомал, Тиотепа, Алтретамин, Мелфалан, Трастузумаб, Лерозол, Фулвестрант, Эксеместан, Ифосфомид, Ритуксимаб, C225, Кампат, лейковорин, дексаметазон, бикалутамид, хлорамбуцил, летрозол, мегестрол, валрубицин и винвластин.
8. Соединение по п.1 или фармацевтическая композиция по п.2 для применения в способе ингибирования аномального клеточного роста или лечения гиперпролиферативного расстройства у млекопитающего.
9. Способ ингибирования Никотинамидфосфорибозилтрансферазы (“NAMPT”) у пациента путем введения терапевтически эффективного количества по меньшей мере одного соединения по п.1.
10. Способ лечения, профилактики, ингибирования или устранения заболевания или состояния у пациента путем ингибирования NAMPT у указанного пациента путем введения терапевтически эффективного количества по меньшей мере одного соединения по п.1, где указанное заболевание или состояние выбрано из группы, включающей рак, рак яичника, рак молочной железы, рак матки, рак толстой кишки, цервикальный рак, рак легкого, рак предстательной железы, рак кожи, рак мочевого пузыря, рак поджелудочной железы, лейкоз, лимфому, болезнь Ходжкина, немелкоклеточный рак легкого, мелкоклеточный рак легкого, множественную миелому, лейкозы, лимфомы, раковые заболевания сквамозноклеточного типа, рак почки, рак уретры и мочевого пузыря, рак головы и шеи, и раковые заболевания головного мозга и центральной нервной системы.
11. Применение соединения по п.1 или фармацевтической композиции по п.2 для лечения гиперпролиферативного расстройства у млекопитающего.
12. Применение соединения по п.1 или фармацевтической композиции по п.2 для получения лекарственного средства для лечения рака.
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37981210P | 2010-09-03 | 2010-09-03 | |
US37981910P | 2010-09-03 | 2010-09-03 | |
US61/379,812 | 2010-09-03 | ||
US61/379,819 | 2010-09-03 | ||
US38603710P | 2010-09-24 | 2010-09-24 | |
US38604410P | 2010-09-24 | 2010-09-24 | |
US61/386,037 | 2010-09-24 | ||
US61/386,044 | 2010-09-24 | ||
US201161478995P | 2011-04-26 | 2011-04-26 | |
US61/478,995 | 2011-04-26 | ||
US201161480423P | 2011-04-29 | 2011-04-29 | |
US61/480,423 | 2011-04-29 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013114844A Division RU2617424C2 (ru) | 2010-09-03 | 2011-09-02 | Новые соединения и композиции для ингибирования nampt |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2016116533A3 RU2016116533A3 (ru) | 2018-11-30 |
RU2016116533A true RU2016116533A (ru) | 2018-11-30 |
Family
ID=44653564
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016116533A RU2016116533A (ru) | 2010-09-03 | 2011-09-02 | Новые соединения и композиции для ингибирования nampt |
RU2013114844A RU2617424C2 (ru) | 2010-09-03 | 2011-09-02 | Новые соединения и композиции для ингибирования nampt |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013114844A RU2617424C2 (ru) | 2010-09-03 | 2011-09-02 | Новые соединения и композиции для ингибирования nampt |
Country Status (13)
Country | Link |
---|---|
US (4) | US20130273034A1 (ru) |
EP (1) | EP2611777B1 (ru) |
JP (2) | JP6038792B2 (ru) |
KR (1) | KR20130114653A (ru) |
CN (2) | CN106986856A (ru) |
AR (1) | AR082887A1 (ru) |
AU (1) | AU2011295724B2 (ru) |
BR (1) | BR112013004858A8 (ru) |
CA (1) | CA2809391A1 (ru) |
MX (1) | MX342481B (ru) |
RU (2) | RU2016116533A (ru) |
TW (1) | TW201217359A (ru) |
WO (1) | WO2012031196A1 (ru) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2809391A1 (en) | 2010-09-03 | 2012-03-08 | Genentech, Inc. | 4-{[(pyridin-3-yl-methyl)aminocarbonyl]amino}benzene-sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer |
US20140294805A1 (en) | 2010-09-03 | 2014-10-02 | Kenneth W. Bair | Novel compounds and compositions for the inhibition of nampt |
MX2013005454A (es) | 2010-11-15 | 2013-06-24 | Abbvie Inc | Inhibidores de nampt y rock. |
AR082889A1 (es) | 2011-05-09 | 2013-01-16 | Forma Therapeutics Inc | Compuestos y composiciones para la inhibicion de nampt |
US9822129B2 (en) | 2012-03-02 | 2017-11-21 | Genentech, Inc. | Amido spirocyclic amide and sulfonamide derivatives |
SG10201701894SA (en) | 2012-03-02 | 2017-05-30 | Genentech Inc | Amido-Benzyl Sulfone and Sulfoxide Derivatives |
EP2852585A1 (en) * | 2012-05-11 | 2015-04-01 | AbbVie Inc. | Nampt inhibitors |
US9187472B2 (en) * | 2012-05-11 | 2015-11-17 | Abbvie Inc. | NAMPT inhibitors |
WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
US9296723B2 (en) | 2012-05-11 | 2016-03-29 | Abbvie Inc. | NAMPT inhibitors |
CN104768931A (zh) * | 2012-06-27 | 2015-07-08 | 向日葵研究有限责任公司(美国) | 化合物及其治疗用途 |
CA2888360A1 (en) * | 2012-10-15 | 2014-04-24 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
WO2014074715A1 (en) * | 2012-11-07 | 2014-05-15 | Genentech, Inc. | Cyclopropyl amide derivatives |
EA201692091A1 (ru) | 2014-04-18 | 2017-04-28 | Милленниум Фармасьютикалз, Инк. | Хиноксалиновые соединения и их применение |
US20170204092A1 (en) | 2014-07-23 | 2017-07-20 | Aurigene Discovery Technologies Limited | 4,5-dihydroisoxazole derivatives as nampt inhibitors |
EP3247705B1 (en) | 2015-01-20 | 2019-11-20 | Millennium Pharmaceuticals, Inc. | Quinazoline and quinoline compounds and uses thereof as nampt inhibitors |
US20180290979A1 (en) * | 2015-04-30 | 2018-10-11 | Kyoto University | Composition having compound accelerating phosphorylation of ampk as effective component |
EP3331894B1 (en) | 2015-08-05 | 2021-02-17 | Metro International Biotech, LLC | Nicotinamide mononucleotide derivatives and their uses |
GB2542881B (en) | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
RS64027B1 (sr) * | 2016-03-22 | 2023-03-31 | Helsinn Healthcare Sa | Benzenesulfonil-asimetrične uree i njihove medicinske upotrebe |
KR101869794B1 (ko) * | 2016-07-20 | 2018-06-21 | 연세대학교 산학협력단 | 내성암, 재발암 또는 전이암의 예방 또는 치료용 약학 조성물 |
IL291810A (en) | 2016-10-18 | 2022-06-01 | Seagen Inc | Targeted administration of nicotinamide adenine dinucleotide reductase pathway inhibitors |
BR112019022445A2 (pt) | 2017-04-27 | 2020-05-12 | Seattle Genetics, Inc. | Composição de conjugado ligante-fármaco, formulação, método para inibir a multiplicação de uma célula tumoral ou célula cancerosa ou causar apoptose em uma célula tumoral ou cancerosa, e, composto de conector de fármaco |
EP3412651A1 (en) * | 2017-06-06 | 2018-12-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Inhibitors of rac1 and uses thereof for inducing bronchodilatation |
WO2019089478A1 (en) * | 2017-10-30 | 2019-05-09 | Neuropore Therapies, Inc. | Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof |
WO2019139869A1 (en) | 2018-01-10 | 2019-07-18 | Cura Therapeutics Llc | Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications |
US11180521B2 (en) | 2018-01-30 | 2021-11-23 | Metro International Biotech, Llc | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof |
KR101937126B1 (ko) * | 2018-06-15 | 2019-01-10 | 연세대학교 산학협력단 | 내성암, 재발암 또는 전이암의 예방 또는 치료용 약학 조성물 |
CN112654608B (zh) | 2018-07-05 | 2024-05-07 | 桑福德伯纳姆普利斯医学发现研究所 | 具有脲结构的稠环化合物 |
US20220125814A1 (en) * | 2019-03-21 | 2022-04-28 | Fred Hutchinson Cancer Research Center | Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor |
US10618927B1 (en) | 2019-03-22 | 2020-04-14 | Metro International Biotech, Llc | Compositions and methods for modulation of nicotinamide adenine dinucleotide |
US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
EP3997068A1 (en) * | 2019-07-11 | 2022-05-18 | Cura Therapeutics, LLC | Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases |
ES2828464A1 (es) * | 2019-11-26 | 2021-05-26 | Univ Murcia | Inhibidores de la muerte celular por parthanatos para ser usados en el tratamiento de las enfermedades inflamatorias de la piel |
FR3103702B1 (fr) * | 2019-11-28 | 2022-02-11 | Nuvamid Sa | Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes |
WO2021126902A1 (en) * | 2019-12-20 | 2021-06-24 | Merck Sharp & Dohme Corp. | Amido-substituted heterocyclic compounds and methods of use thereof for the treatment of herpes viruses |
US20240124466A1 (en) * | 2020-12-11 | 2024-04-18 | Vova Ida Therapeutics, Inc. | Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders |
IL308577A (en) | 2021-05-27 | 2024-01-01 | Metro Int Biotech Llc | Crystalline solids of nicotinic acid mononucleotides and their esters and methods for their preparation and use |
CN113278409B (zh) * | 2021-06-22 | 2022-04-29 | 西南石油大学 | 一种高温酸化缓蚀剂 |
CN114890990B (zh) * | 2022-04-13 | 2024-01-16 | 中国人民解放军海军军医大学 | 一种化合物及在制备nampt蛋白自噬降解剂中的应用 |
CN115286617B (zh) * | 2022-06-24 | 2024-04-30 | 中国人民解放军海军军医大学 | 一种靶向降解nampt的protac化合物及其应用 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3931203A (en) | 1973-03-19 | 1976-01-06 | Rohm And Haas Company | 3-Pyridylmethyl aryl urea rodenticides |
AR205697A1 (es) | 1973-03-19 | 1976-05-31 | Rohm & Haas | Nuevos compuestos rodenticidas de 1 - (3 - piridilmetil) - 3 - (4 - substituido fenil o 4-nitronaftil) ureas composicion que los comprende y procedimiento para prepararlos |
DE2334355A1 (de) | 1973-07-06 | 1975-01-16 | Hoechst Ag | Diphenylharnstoffderivate und ihre herstellung |
US3994905A (en) * | 1974-04-11 | 1976-11-30 | Rohm And Haas Company | 3-Pyridylmethyl aryl urea rodenticides |
US4659724A (en) | 1982-12-30 | 1987-04-21 | Union Carbide Corporation | Certain 1-[4-(5-cyano-2-pyridyloxy)phenyl-benzoyl ureas having pesticidal properties |
DE19624668A1 (de) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
DE19624704A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalkansäureamide |
DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
DE19756236A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide |
DE19756212A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide |
DE19756261A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide |
DE19756235A1 (de) | 1997-12-17 | 1999-07-01 | Klinge Co Chem Pharm Fab | Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide |
GB9904275D0 (en) * | 1999-02-24 | 1999-04-21 | Cancer Res Campaign Tech | Anti-cancer compounds |
EP1031564A1 (en) | 1999-02-26 | 2000-08-30 | Klinge Pharma GmbH | Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy |
DE10053794A1 (de) * | 2000-10-30 | 2002-05-08 | Bayer Ag | Neue Verwendung für Amino- und Amidosulfonamide |
US7238813B2 (en) | 2000-11-29 | 2007-07-03 | Smithkline Beecham Corporation | Chemical compounds |
ES2200617B1 (es) * | 2001-01-19 | 2005-05-01 | Almirall Prodesfarma, S.A. | Derivados de urea como antagonistas de integrinas alfa 4. |
US6949567B2 (en) | 2001-02-26 | 2005-09-27 | 4Sc Ag | Compounds for the treatment of protozoal diseases |
DE10109204A1 (de) | 2001-02-26 | 2002-09-19 | 4Sc Ag | Verbindungen zur Behandlung von Protozoen-Erkrankungen |
WO2003059872A1 (en) | 2001-12-31 | 2003-07-24 | Bayer Pharmaceuticals Corporation | Avb3 and avb5 integrin antagonists and methods of treating diseases or conditions associated with avb3 and avb5 integrins |
EP1348434A1 (en) | 2002-03-27 | 2003-10-01 | Fujisawa Deutschland GmbH | Use of pyridyl amides as inhibitors of angiogenesis |
US7615563B2 (en) | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
WO2005048953A2 (en) | 2003-11-13 | 2005-06-02 | Ambit Biosciences Corporation | Amide derivatives as kinase modulators |
TW200600492A (en) | 2004-05-18 | 2006-01-01 | Achillion Pharmaceuticals Inc | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
EP1907367A4 (en) | 2005-04-18 | 2011-05-11 | Saeed R Khan | DEVELOPMENT AND SYNTHESIS OF NEW TUBULIN POLYMERIZATION INHIBITORS: BENZOYLPHENYL HARVEST (BPU) SULFUR ANALOGUE |
BRPI0617513A2 (pt) | 2005-10-20 | 2011-07-26 | Sumitomo Chemical Co | compostos de benzoilurÉia, processo para a produÇço e uso dos mesmos e mÉtodo para controlar pestes |
EP2069294A1 (en) | 2006-09-28 | 2009-06-17 | Arete Therapeutics, INC. | Soluble epoxide hydrolase inhibitors |
US8450348B2 (en) | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
RU2011111728A (ru) * | 2008-08-29 | 2012-10-10 | Топотаргет А/С (Dk) | Новые производные мочевины и тиомочевины |
FR2943669B1 (fr) | 2009-03-24 | 2011-05-06 | Sanofi Aventis | Derives de nicotinamide,leur preparation et leur application en therapeutique |
WO2010142735A1 (en) * | 2009-06-09 | 2010-12-16 | Topotarget A/S | Pyridinyl derivatives as inhibitors of enzyme nicotinamide phosphoribosyltransferase |
MX2012010011A (es) * | 2010-03-01 | 2012-10-05 | Myrexis Inc | Compuestos y usos terapeuticos de los mismos. |
US20140294805A1 (en) | 2010-09-03 | 2014-10-02 | Kenneth W. Bair | Novel compounds and compositions for the inhibition of nampt |
US9676721B2 (en) | 2010-09-03 | 2017-06-13 | Forma Tm, Llc | Compounds and compositions for the inhibition of NAMPT |
CA2809391A1 (en) | 2010-09-03 | 2012-03-08 | Genentech, Inc. | 4-{[(pyridin-3-yl-methyl)aminocarbonyl]amino}benzene-sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer |
CN103717574B (zh) | 2011-05-04 | 2017-02-22 | 福马Tm有限责任公司 | 用于抑制nampt的新化合物和组合物 |
AR082889A1 (es) | 2011-05-09 | 2013-01-16 | Forma Therapeutics Inc | Compuestos y composiciones para la inhibicion de nampt |
WO2013127268A1 (en) | 2012-03-02 | 2013-09-06 | Genentech,Inc. | Amido-benzyl sulfone and sulfonamide derivatives |
SG10201701894SA (en) | 2012-03-02 | 2017-05-30 | Genentech Inc | Amido-Benzyl Sulfone and Sulfoxide Derivatives |
US9458172B2 (en) | 2012-03-02 | 2016-10-04 | Kenneth W Bair | Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives |
WO2013130935A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Amido-benzyl sulfoxide derivatives |
WO2013130943A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Alkyl-and di-substituted amido-benzyl sulfonamide derivatives |
US9822129B2 (en) | 2012-03-02 | 2017-11-21 | Genentech, Inc. | Amido spirocyclic amide and sulfonamide derivatives |
-
2011
- 2011-09-02 CA CA2809391A patent/CA2809391A1/en not_active Abandoned
- 2011-09-02 EP EP11758024.1A patent/EP2611777B1/en not_active Not-in-force
- 2011-09-02 CN CN201610866074.2A patent/CN106986856A/zh active Pending
- 2011-09-02 RU RU2016116533A patent/RU2016116533A/ru unknown
- 2011-09-02 CN CN201180053248.9A patent/CN103270023B/zh not_active Expired - Fee Related
- 2011-09-02 TW TW100131860A patent/TW201217359A/zh unknown
- 2011-09-02 JP JP2013527339A patent/JP6038792B2/ja not_active Expired - Fee Related
- 2011-09-02 AR ARP110103220A patent/AR082887A1/es unknown
- 2011-09-02 US US13/820,496 patent/US20130273034A1/en not_active Abandoned
- 2011-09-02 WO PCT/US2011/050320 patent/WO2012031196A1/en active Application Filing
- 2011-09-02 RU RU2013114844A patent/RU2617424C2/ru active IP Right Revival
- 2011-09-02 BR BR112013004858A patent/BR112013004858A8/pt not_active Application Discontinuation
- 2011-09-02 AU AU2011295724A patent/AU2011295724B2/en not_active Ceased
- 2011-09-02 KR KR1020137008447A patent/KR20130114653A/ko not_active Application Discontinuation
- 2011-09-02 MX MX2013002431A patent/MX342481B/es active IP Right Grant
-
2016
- 2016-08-22 JP JP2016161655A patent/JP2017019825A/ja active Pending
-
2018
- 2018-06-14 US US16/008,378 patent/US10329275B2/en active Active
-
2019
- 2019-05-22 US US16/419,333 patent/US10647695B2/en active Active
-
2020
- 2020-03-20 US US16/824,885 patent/US11279687B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
RU2016116533A3 (ru) | 2018-11-30 |
AU2011295724B2 (en) | 2016-05-12 |
RU2617424C2 (ru) | 2017-04-25 |
WO2012031196A1 (en) | 2012-03-08 |
US20180291000A1 (en) | 2018-10-11 |
RU2013114844A (ru) | 2014-10-10 |
US10329275B2 (en) | 2019-06-25 |
JP2017019825A (ja) | 2017-01-26 |
CN106986856A (zh) | 2017-07-28 |
JP6038792B2 (ja) | 2016-12-07 |
TW201217359A (en) | 2012-05-01 |
AR082887A1 (es) | 2013-01-16 |
WO2012031196A9 (en) | 2013-06-13 |
AU2011295724A1 (en) | 2013-05-02 |
US20190270721A1 (en) | 2019-09-05 |
EP2611777A1 (en) | 2013-07-10 |
KR20130114653A (ko) | 2013-10-17 |
JP2013536868A (ja) | 2013-09-26 |
CN103270023B (zh) | 2016-11-02 |
US20130273034A1 (en) | 2013-10-17 |
US20200283403A1 (en) | 2020-09-10 |
CA2809391A1 (en) | 2012-03-08 |
AU2011295724A8 (en) | 2013-06-20 |
CN103270023A (zh) | 2013-08-28 |
BR112013004858A2 (pt) | 2016-06-07 |
US10647695B2 (en) | 2020-05-12 |
MX2013002431A (es) | 2013-06-03 |
EP2611777B1 (en) | 2016-05-11 |
US11279687B2 (en) | 2022-03-22 |
MX342481B (es) | 2016-09-30 |
BR112013004858A8 (pt) | 2018-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016116533A (ru) | Новые соединения и композиции для ингибирования nampt | |
RU2013153529A (ru) | Новые соединения и композиции для ингибирования nampt | |
CN106715415B (zh) | 3-氨基-1,5,6,7-四氢-4h-吲哚-4-酮 | |
HRP20191860T1 (hr) | Derivati 2-hidroksi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etan-1-ona i srodni spojevi kao inhibitori sintaze masnih kiselina (fasn) za liječenje raka | |
RU2013114848A (ru) | Гуанидиновые соединения и композиции для ингибирования nampt | |
KR102079406B1 (ko) | Lsd1 억제제로서의 (헤테로)아릴 사이클로프로필아민 화합물 | |
US20040014782A1 (en) | Combination therapy for the treatment of diseases involving inflammatory components | |
EP3277276B1 (en) | Methods of administering glutaminase inhibitors | |
CA2759951C (en) | Substituted phenylureas and phenylamides as vanilloid receptor ligands | |
WO2016197114A1 (en) | Tank-binding kinase-1 protacs and associated methods of use | |
HRP20170411T1 (hr) | Amido spirocilični amidni i sulfonamidni derivati | |
CA2570942A1 (en) | Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof, and use of the same as medicament | |
JP2000504722A (ja) | Il―8レセプターアンタゴニスト | |
EP1797071A1 (de) | Carbonylverbindungen verwendbar als inhibitoren des koagulationsfaktors xa | |
RU2292344C2 (ru) | Производные пиридилцианогуанидинов и фармацевтическая композиция на их основе | |
SK16252001A3 (sk) | Aromatická sulfónhydroxámová kyselina ako inhibítor metaloproteiázy | |
BG63628B1 (bg) | Заместени (сулфинова киселина, сулфонова киселина, сулфониламино или сулфиниламино) n-[(аминоиминометил) фенилалкил]-азахетероциклиламидни съединения | |
EA026785B1 (ru) | Модуляторы индоламин 2,3-диоксигеназы и способы их применения | |
WO2006032342A2 (de) | Arzneimittel enthaltend carbonylverbindungen sowie deren verwendung | |
MXPA06006210A (es) | Esteres de acido hidroxamico y uso farmaceutico de los mismos. | |
JP2007513098A5 (ru) | ||
DE60019296T2 (de) | Substituierte polyzyklische aryl und heteroarylpyrazinone zur selektiven hemmung von der blutgerinnungskaskade | |
EP3049394A1 (de) | Substituierte phenylalanin-derivate als faktor xia modulatoren | |
JP2005531560A (ja) | シアノグアニジンプロドラッグ | |
JP2005538949A (ja) | シアノグアニジンプロドラッグ |